Clara Curiel-Lewandrowski, Susan M. Swetter, Janine G. Einspahr, Chiu-Hsieh Hsu, Ray Nagle, Paul Sagerman, Joseph Tangrea, Howard Parnes, David S. Alberts and Hsiao-Hui Chow Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma Cancer 118
Article first published online: 17 MAY 2012 | DOI: 10.1002/cncr.27540
Exposure to oral sulindac at 150 mg twice a day for 8 weeks in patients with atypical nevi results in measurable levels of sulindac and its metabolites in melanocytic nevi. Sulindac intervention did not result in significant changes in vascular endothelial growth factor A expression but marginally increased the expression of the apoptotic marker cleaved caspase-3 in atypical nevi.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.